Study protocol for a randomised controlled trial to determine the efficacy of lisdexamfetamine for the treatment of acute methamphetamine withdrawal in inpatient settings

Introduction Harms due to methamphetamine use disorder (MAUD) are rising globally. Untreated withdrawal symptoms perpetuate the cycle of dependence and are a barrier to treatment. There is no pharmacotherapy approved for methamphetamine withdrawal. Lisdexamfetamine (LDX) dimesylate has potential as...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Dan I Lubman, Jonathan Brett, Andrew Carr, Paul S Haber, Adrian J Dunlop, Nicholas Lintzeris, Frances R Levin, Nadine Ezard, Rebecca McKetin, Brendan Clifford, Michael Doyle, Krista J Siefried, Nathan Taylor, Michael Christmass, Steven Shoptaw, Shalini Arunogiri, Liam S Acheson, Mark Donoghoe, Jack Nagle
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	BMJ Publishing Group 2025-11-01
سلاسل:	BMJ Open
الوصول للمادة أونلاين:	https://bmjopen.bmj.com/content/15/11/e107242.full
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!